Amgen Details Phase 3 Dazodalibep Results in Sjogren Disease

Company Amgen Event Type Detailed Phase 3 results (OASIZ-301) Modality Fusion protein Asset Dazodalibep Target CD40L Disease Area Sjögren disease Summary Recovered 36-hour item: Amgen disclosed detailed randomized Phase 3 OASIZ-301 results November 11 after earlier topline news. Both dazodalibep dose schedules improved systemic disease…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *